Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sangamo Therapeutics, Inc.
< Previous
1
2
Next >
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 21, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 03, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 27, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
October 12, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 30, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 04, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
July 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
July 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
June 01, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 05, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
April 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
April 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
March 29, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
February 24, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
February 17, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
February 07, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
January 06, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 12, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
PFE
SGMO
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
December 12, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
November 09, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
November 04, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
November 04, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
October 28, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
August 31, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
August 09, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 05, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
July 29, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
May 24, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.